Get started
CRISPR Therapeutics AGCRISPR Therapeutics AGCRISPR Therapeutics AG

CRISPR Therapeutics AG

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

CRSP trade ideas

Looking for the next Amazon or Tesla to invest at the Start?CRISPR Therapeutics - revenue projection = Massive I am accumulating shares. you may want to start looking into CrSp.Let's calculate the revenue potential for CRISPR Therapeutics based on their approved therapy and pipeline: THERAPY 1: BEING ROLLED OUT AND APPROVED IN THE USA AND EUROPE Casgevy (approved for sickle cell disease and beta-thalassemia): Price per therapy: $2.2 million Potential patient pool: 70 million Assuming 2% adoption: 1.4 million patients Potential revenue: $3.08 trillion THERAPY 2: CTX310 (Phase 1 for cardiovascular disease): Assuming similar pricing and 1% adoption of global cardiovascular patients (520 million)Potential revenue: $1.144 trillion THERAPY 3: CTX320 (Phase 1 for elevated Lp(a)):20% of global population has elevated Lp(a), assuming 0.5% adoption Potential revenue: $1.716 trillion THERAPY 4: CTX340 and CTX450 (preclinical): Assuming more modest adoption due to earlier stage, estimate $500 billion each.Combined potential revenue: $1 trillion Total potential revenue: $6.94 trillion ASSUMPTION OF REVENUE POTENTIAL DISCOUNTED TO NET PRESENT VALUE AND THEN CALCULATION OF SHARE PRICE ASSUMPTION GIVEN THIS DATA: Assuming this revenue is spread over 10 years and using a conservative 10% discount rate for NPV calculation:NPV = $6.94 trillion / (1.1^5) ≈ $4.31 trillion CRISPR Therapeutics has approximately 79 million shares outstanding.Value per share: $4.31 trillion / 79 million ≈ $54,557 Projected share price (multiplied by 25, 25 is the mlptiple at which companies trade on average): $1,363,925 This calculation suggests an extremely high potential value. Competition, many copy cats and swindlers purporting the expertise, as usual with Biotech, you remember INO Inovio and that Korean Doctor, a fraud in my opinion (the stock wen from $33 to almost zero). Well CRSP is lead by two Nobel Prize winners, Harvard is in the mix and the Swiss are financing it, and they have already 44 Therapy Centers, and licensing the technology very quickly. This company is the real deal. Careful investing in the rest of the space, Pfizer already flopped, imagine Pfizer, that should tell you that this BioTech Space is only for salient technologies. When people go back to see how they would have done with Amazon or Netflix, well here you have another technology company that can very well outdo them all. Short Interest: 19.39 million shares Float: Approximately 83.94 million shares (calculated from 23.10% of float shorted) Cash: $2.0 billion as of June 2024 Growth Rate: Revenue growth of 19% over the past year Debt: Zero debt reported Volume: Average trading volume of 1.48 million shares per day Days to Cover: 14.8 days Additional information: Short Interest Ratio: 13.31 Days to Cover Short Interest % of Float: 23.10% Cash Burn: $129 million in the last year Cash Runway: Several years based on current burn rate Market Capitalization: Approximately $4.2-$4.3 billion The P/E ratio is not provided in the search results, which is common for biotechnology companies that may not yet have consistent earnings. THE PERFECT CANDIDATE FOR A MASSIVE SHORT SQUEEZE. #investments, #CRSP, #Crispr, #Therapy, #Therapeutics, #Get, #Rich, #Biotech, #Technology, #Medicine, #SickelCell link to article: "https://www.linkedin.com/pulse/looking-next-amazon-tesla-invest-very-beginning-well-read-s-sc-n--0r8be/?trackingId=o%2B1DocTdTi%2BO%2Bwk%2FqKV1yA%3D%3D"
NASDAQ:CRSPLong
by imcnf5c4ff
Cound this be ? and yet maybe is will.....CRISPR Therapeutics - the next Trillion Dollar Company. November 14, 2024 Investing ins SpaceX before it goes Public.... This is good advice !!! Space is the new War Economy, I mead the defense machine needs a new business line, and space is more profitable than any war economy X 50 - war economy today 34 Trillion Annually according to my calculations. Space realignment, so much more - the 1st massive breakthrough will be in biotech, breakthrough, I mean extremely profitable manufacturing will be in bio-manufacturing of parts for transplant, oh yeah. it is coming. In the meantime read my posts on Crispr Therapeutics. Truly Amazing times. Go to my profile and sort for posts, all three some 10 - describing the founders winning the Nobel Price for Chemistry, their first products being approved by the FDA and expanding revenue, the pipeline, and lastly an NPV Valuations of $1,075 per share today.... that is coming, kid you not. This is the collection of post I made about CRISPR THERAPEUTICS - It discusses all the positives about this stock. The positives are truly overwhelming in quantity, in speed of development, in how this company will upgrade life itself, from humans to nature, prepare for a quantum leap. Even terraforming Mars, it is all in the cards for CIRSPR Therapeutics, ticker CrSp, traded in USA Markets. Oh, before I forget, these posts also discuss the acceleration of development of new therapies, because of AI. CRISPR THERAPEUTICS is expected to greatly accelerate discoveries and implementation of therapies The integration of AI with CRISPR technology is poised to revolutionize medicine by enabling precise, effective, and personalized therapies. AI enhances the CRISPR genome editing process by optimizing guide RNA design, predicting outcomes, and minimizing off-target effects, leading to safer and more efficient treatments for diseases such as sickle cell anemia and cancer. Transformation Timeline • Short-Term (1-3 years): Expect advancements in existing therapies, with AI improving the precision of CRISPR applications in clinical settings. • Medium-Term (3-5 years): Introduction of tailored gene therapies based on individual genetic profiles, leveraging AI for real-time data analysis. • Long-Term (5+ years): A shift towards a new paradigm of medicine where AI-driven CRISPR technologies dominate, making chemical-based processes seem outdated. The synergy between AI and CRISPR is expected to accelerate the development of next-generation therapies, transforming healthcare into a more personalized and effective approach








“CRISPR Therapeutics Shares Hold Strong Potential: The Calculated NPV Surpasses $1,073!” CRISPR Therapeutics commercializes its FDA-approved therapies primarily through strategic partnerships, particularly with Vertex Pharmaceuticals. Here’s how the commercialization process works: Commercialization Strategy 1. Partnership with Vertex Pharmaceuticals: • Vertex leads the global development, manufacturing, and commercialization of CTX001 (exagamglogene autotemcel) for sickle cell disease and transfusion-dependent beta-thalassemia. • Under their agreement, Vertex is responsible for 60% of program costs and profits, while CRISPR retains 40% . 2. Revenue Structure: • CRISPR received a $900 million upfront payment from Vertex, with potential milestone payments of up to $200 million upon regulatory approval . • CRISPR also benefits from royalties on future sales of CTX001 and other products developed under this partnership. 3. Regulatory Approvals: • CRISPR has successfully submitted Biologics License Applications (BLAs) for exa-cel, which have received priority review from the FDA, enhancing the speed of commercialization . 4. Market Access and Distribution: • The collaboration allows CRISPR to leverage Vertex’s established infrastructure for market access and distribution, ensuring that therapies reach patients effectively. Future Commercialization Efforts • CRISPR is also advancing its pipeline of therapies in various stages of clinical trials, including CAR T-cell therapies like CTX110 and CTX131, which are expected to follow a similar commercialization strategy through partnerships or independent efforts once they receive regulatory approval . This collaborative approach maximizes CRISPR’s resources while allowing it to focus on innovation and development in gene editing technologies.



Crispr therapeutics (CRSP) Currently Approved Therapies 1. Casgevy (exagamglogene autotemcel): Approved for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). 2. Zolgensma (onasemnogene abeparvovec-xioi): Gene therapy for spinal muscular atrophy. 3. Kymriah (tisagenlecleucel): CAR T-cell therapy for certain types of leukemia and lymphoma. 4. Yescarta (axicabtagene ciloleucel): CAR T-cell therapy for large B-cell lymphoma. 5. Luxturna (voretigene neparvovec-rzyl): Gene therapy for inherited retinal disease. Pending Approval Therapies 1. CTX001 (exagamglogene autotemcel): • Indications: Sickle cell disease and transfusion-dependent beta thalassemia. • Estimated Approval Dates: • SCD: December 8, 2023 (FDA) • TDT: March 30, 2024 (FDA) 2. CTX110: Allogeneic CAR T-cell therapy targeting CD19. • Estimated Approval Date: TBD, currently in Phase 2 trials. 3. CTX131: Allogeneic CAR T-cell therapy targeting CD70. • Estimated Approval Date: TBD, currently in Phase 1 trials. 4. CTX310 and CTX320: Targeting lipoprotein(a) for cardiovascular diseases. • Estimated Clinical Entry: First half of 2024. These therapies represent significant advancements in gene editing and cellular therapies, with CTX001 being particularly notable as the first CRISPR-based therapy expected to gain FDA approval CRSP TICKER SYMBOL - To arrive at a theoretical share value for CRISPR Therapeutics (CRSP), we can use the projected future revenues and the company’s market capitalization. Current Market Data • Current Share Price: $51.62 • Market Capitalization: Approximately $4.4 billion Revenue Projections Using the speculative revenue projections: • 2024: $4 billion • 2028: $7.1 billion • 2030: $9.5 billion • 2034: $17.8 billion Valuation Method Assuming a price-to-sales (P/S) ratio of 18.93 (as per current data) for future revenue projections, we can estimate the theoretical share value. Theoretical Share Value Calculation 1. Projected Revenue for 2028: $7.1 billion 2. Estimated Market Cap in 2028: 3. Shares Outstanding: Approximately 85 million . 4. Theoretical Share Value in 2028: Discounting to Present Value To find the present value of this share price using a discount rate of 10% over 4 years (from 2024 to 2028): Conclusion The theoretical present share value of CRISPR Therapeutics today could be approximately $1,073, based on speculative future revenues and current market conditions. This projection assumes successful commercialization of their therapies and sustained growth in the gene editing market The CRISPR THERAPIITICS market is projected to grow significantly, with estimates suggesting it will reach approximately $17.8 billion by 2034, up from $3.4 billion in 2023, reflecting a compound annual growth rate (CAGR) of 16.1% from 2024 to 2034. Speculative Revenue Projections • 2024: $4 billion • 2028: $7.1 billion • 2030: $9.5 billion (based on a CAGR of 15.6% from 2023) • 2034: $17.8 billion Present Value Calculation Using a discount rate of 10%, the present value (PV) of future cash flows can be estimated as follows: Where is the discount rate and is the number of years until the cash flow occurs. Summary The total present value of projected revenues from CRISPR initiatives could amount to approximately $19.67 billion, indicating a significant potential return on investment in this rapidly evolving market
NASDAQ:CRSPLong
by imcnf5c4ff
4 hour bullish divergence It was pointed out to me earlier that the last time I posted was back in May so I thought I’d pull my finger out and share this one. The company has developed a cure for sickle cell disease, by gene editing, this disease is seriously debilitating and affects millions of people of African descent, this is a game changer for people with this disease. The company are still loss making but this groundbreaking technology has the potential to cure other previously incurable diseases. Cathie Wood has been accumulating shares in her Ark fund, it has huge potential, picked up a few shares earlier today
NASDAQ:CRSPLong
by RIckAshby
CRSP | Time to Start Accumulating | LONGCRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
NASDAQ:CRSPLong
by DivergenceSeeker
CRSP Trying to break past weekly supply zone! CRISPR Therapeutics is an amazing company that focuses on cloning and gene modification. It is the future of medicine. I like to buy CRISPR at the TrendCloud Crossovers on the 1 hour chart. We are pulling back into a weekly demand zone and looking for option chains around $49. If you want to lean more about investing in stocks for long-term wealth building then click the link in my profile for the best news and setups using TrendCloud.
NASDAQ:CRSP
by thechrisjuliano
CRISPR idea, more long termSo the odd event that one of their key employees as far as I could tell just decided to leave did spark the selloff recently. If it continues then dont bother with this stock. But if we see strength then maybe it will go up again. Especially if they continue with good earnings and success overall. I know, top tier analys. But just an idea. My goal is usually 100% up and thats it. But if they continue to provide good stuff then I dont see why this wouldnt go to new ath
NASDAQ:CRSPLong
by DagligHandel
CRISPR Therapeutics ($CRSP) Impressive Stock Performance CRISPR Therapeutics (NASDAQ: NASDAQ:CRSP ) has climbed more than 60% this year and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their blood disorders candidate, exacel, and investors bet on potential regulatory approvals to follow. All of this marks just the beginning of a great opportunity for long-term investors. Let's check out three reasons to buy CRISPR Therapeutics like there's no tomorrow. CRISPR Therapeutics recently said it's shifting its focus to its next-generation immuno-oncology candidates and dropping its initial ones -- including a candidate that was in late-stage development. Technical Analysis CRISPR Therapeutics has broken the ceiling of the falling trend. NASDAQ:CRSP is trading near the top of its 52-week range and above its 200-day simple moving average. The pivot points show that the current price is above the pivot point of 61.59 USD, indicating a bullish bias. Investors have been pushing the share price higher, and the stock still appears to have upward momentum.
NASDAQ:CRSPLong
by DEXWireNews
LONG: Perfect High Tight Flag forming on CRSPNASDAQ:CRSP High tight flags were first observed by legendary investor William O'Neil of IBD and CANSLIM fame. Check out the pattern on CRSP, showing an 86.12% gain in just 22 days. Notice the consolidation of 7.02% over the past week forming the high tight flag. Watch for a breakout on strong volume above the leading edge of the wedge for exponential gains. Predict that this will rise to above 120% in the coming weeks. Read more about the launch of an approved product driving these gains at Zacks .
NASDAQ:CRSPLong
by HighTightFlags
4
CRSP: Big orrection after the next rally, but buy-the-dip.I believe that CRSP (Crispr Therapeutics) is about to undergo a severe correction soon. I scaled into this stock during the latter part of 2022 and the first part of 2023 and it is up nearly 70% and has generated about 40% of pure alpha for me relative to the SPX. So this has been an amazing performer for my total portfolio. I believe this run may be nearing a pullback and I expect the correction to be a very severe one. My suggestion is that this will form a triple-bottom/inverse head-and-shoulders pattern because this will be a subwave 2 correction and in theory, it should not overthrow the recent low by very much. I think the post-correction rally will be sizeable (it'll be a macro Wave 3) and the catalyst for this rally will be the steady trend of slowly improving earnings that they have demonstrated over the past year. (3 successive quarters of positive earnings calls - this has not been achieved since 2017) So, in essence, presuming nothing else changes, I believe we should buy the next dip for a significant Wave 3 rally that will exceed the all-time highs. In the meantime, expect lots of volatility, if you don't have the stomach for taking drawdowns or losses in the interim, you may want to sell the next rally so that you can buy back in. I will probably pursue this course of action myself purely as a matter of greed to preserve the alpha I have managed to capture. Happy biotech trading!
NASDAQ:CRSPLong
by RogueEconomics